AWH Reports Third Quarter 2026 Financial Results

Rhea-AI Summary

Ascend Wellness Holdings (AAWH) reported third-quarter 2026 net revenue of $130.0 million, rising year over year and sequentially. Revenue increased 4.2% from Q3 2025 and 3.1% from Q2 2026. Retail revenue rose 5.5% sequentially to $97.8 million, while wholesale revenue fell 3.6% to $32.2 million. Gross profit reached $53.1 million. The net loss widened to $28.0 million from $9.8 million in Q2, which included a $14.8 million tax-reserve benefit.

Adjusted EBITDA, a non-GAAP earnings measure, was $31.1 million, with a 23.9% margin. Operating cash flow was $5.4 million after a $19.1 million interest payment; quarter-end cash was $63.6 million. Ascend subsequently closed $11 million in mortgage loans and reached 61 stores, including partner locations, exceeding its year-end target of 60. The company expects Q4 revenue growth of 1 to 2% and an adjusted EBITDA margin consistent with Q3.

16 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

2 major · 14 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point$11 million in non-dilutive mortgage loans closed with CF Bank to support expansion and acquisition opportunities. 15% of market cap
• Moderate pointQ3 revenue of $130.0 million increased 4.2% year-over-year and 3.1% sequentially.
• Moderate pointRetail revenue of $97.8 million increased 5.5% sequentially, driven by new store openings.
• Moderate pointGross profit of $53.1 million rose from $45.5 million sequentially; margin increased to 40.8% from 36.1%.
• Moderate pointAdjusted EBITDA of $31.1 million increased from $29.1 million sequentially; margin rose 80 basis points to 23.9%.
• Moderate pointOperating cash flow of $5.4 million reversed $2.0 million of cash used in Q3 2025.
• Moderate pointRetail transactions of approximately 1.7 million increased 6.0% sequentially and 14.9% year-over-year.
• Moderate pointNew Jersey transactions, including partners, increased 18% sequentially and 37% year-over-year.
• Moderate pointNew customer traffic increased 19% sequentially across the retail footprint.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Q4 revenue growth of 1 to 2% is anticipated; adjusted EBITDA margin is expected to match Q3.
• Moderate pointQ3 operating profit of $4.500 million reversed a $1.325 million operating loss in Q3 2025.
• Moderate pointNine-month gross profit increased to $143.462 million from $124.554 million in the comparable 2025 period.
• Moderate pointNine-month operating profit increased to $12.326 million from $0.159 million in the comparable 2025 period.

3 minor points

• Minor point. Forward-looking: it has not happened yet and may not happen.Atlantic Cultivation licensing agreement targets Canadian availability of High Wired and Ozone products in Q1 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.Massachusetts dispensary operations began under a consulting agreement; Ascend expects medical-license access following acquisition closing.
• Minor point. Forward-looking: it has not happened yet and may not happen.Two additional New Jersey partner stores are expected to open in early 2027.

Negative

• Major pointNet loss of $28.0 million widened from $9.8 million sequentially; Q2 included a $14.8 million tax-reserve benefit.
• Major point$11 million mortgage debt carries 8.5% annual interest, matures October 2031, and is secured by five properties. 15% of market cap
• Moderate pointWholesale revenue of $32.2 million fell 3.6% sequentially amid a July work stoppage and lower pricing.
• Moderate pointNet debt was $260.4 million at September 30, 2026.
• Moderate pointQ3 interest expense increased to $21.977 million from $12.562 million in Q3 2025.
• Moderate point$19.1 million semi-annual interest payment was funded during Q3 2026.
• Moderate pointQ3 general and administrative expenses increased to $48.589 million from $44.926 million in Q3 2025.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Capital expenditures totaled $4.8 million in Q3; Ascend expects approximately $20 million for full-year 2026.
• Moderate pointNine-month revenue declined to $373.070 million from $380.035 million in the comparable 2025 period.
• Moderate pointNine-month general and administrative expenses increased to $131.136 million from $124.395 million in the comparable 2025 period.
• Moderate pointNine-month interest expense increased to $63.031 million from $35.810 million in the comparable 2025 period.

3 minor points

• Minor pointMassachusetts acquisition closing remains subject to regulatory approval.
• Minor point. Forward-looking: it has not happened yet and may not happen.Early-2027 New Jersey partner openings remain subject to regulatory timing.
• Minor point. Forward-looking: it has not happened yet and may not happen.Potential major U.S. exchange listing depends on regulatory developments, including broader cannabis rescheduling.

News Explained

The Massachusetts dispensaries are operating under consulting agreements, while acquisition closing and the associated medical-license expansion remain pending.

Stockholders approved a reverse split of Ascend’s Class A common shares, with the board retaining flexibility to choose the ratio and timing; the release describes approval, not a completed split. If implemented, a reverse split reduces share count and proportionally raises the per-share price, without changing company value by itself.

Ascend began operating two Worcester and Shrewsbury dispensaries in October under a consulting agreement while regulatory approval to close the acquisition is pending. Upon closing, the company expects to gain a vertically integrated medical license and extend it to its Massachusetts stores and Athol cultivation facility.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Net revenue grew 4.2% year-over-year and 3.1% sequentially to $130.0 million in Q3 2026

Generated Adjusted EBITDA¹ of $31.1 million and Adjusted EBITDA Margin¹ of 23.9%, as revenue growth drove operating leverage

Ended Q3 with 56 stores and has since exceeded year-end target of 60, with 61 locations now open²

Positive cash flow from operations of $5.4 million, after the $19.1 million semi-annual interest payment

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH-U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator and consumer packaged goods company, today reported its financial results for the quarter ended September 30, 2026 ("Q3 2026"). Financial results are reported in accordance with U.S. generally accepted accounting principles ("GAAP"), and all currency is in U.S. dollars.

Q3 2026 Financial Highlights

• Net revenue was $130.0 million compared to $126.1 million in the second quarter of 2026 ("Q2 2026"), an increase of 3.1% sequentially and 4.2% year-over-year.
  • Retail revenue was $97.8 million compared to $92.7 million in Q2 2026, an increase of 5.5% sequentially, and represented 75.2% of total net revenue, up from 73.5%.
  • Wholesale revenue was $32.2 million compared to $33.4 million in Q2 2026.
• Adjusted Gross Profit Margin¹ of 48.4% of revenue compared to 46.2% in Q2 2026.
• Adjusted EBITDA¹ was $31.1 million compared to $29.1 million in Q2 2026, representing an Adjusted EBITDA Margin¹ of 23.9%.
• Net cash provided by operating activities was $5.4 million, inclusive of the Company's $19.1 million semi-annual interest payment, compared to net cash used in operating activities of $2.0 million in the third quarter of 2025 ("Q3 2025").
• Cash and cash equivalents of $63.6 million as of September 30, 2026.

Q3 2026 Business and Operational Highlights

• Reached 56 retail stores in Q3 2026, including partner owned and operated locations.
• Increased total retail transactions by 6.0% sequentially and 14.9% year-over-year to approximately 1.7 million, the most of any quarter in the Company's history.
  • Transactions across the Company's New Jersey locations, including partners, increased 18% sequentially and 37% year-over-year.
• Maintained its position as the number two brand house by both sales and units across the Company's core markets of Illinois, New Jersey, and Massachusetts, on a combined basis, according to BDSA³.
• • Ozone held the number three position in dollar share and number one in units across those markets, and the Company's share in New Jersey increased approximately 14% sequentially.
• Launched 103 new products in Q3 2026, including the new Ozone Signature premium flower lineup.
• Drove new customer growth and deepened engagement across the Company's network:
  • New customer traffic increased 19% sequentially across retail footprint;
  • Loyalty members accounted for more than 86% of transactions during the quarter, and approximately 32% of new customers enrolled in Ascend's loyalty program; and
  • Pay by bank adoption (Ascend Pay) reached 11.4% of transactions in Q3 2026.
• Received stockholder approval for a reverse stock split of the Company's Class A common shares. This approval, voted on at a special meeting on August 28, 2026, gives the Company's board of directors flexibility to set the ratio and timing of the split. The Company intends to use it to support a potential listing on a major U.S. exchange, subject to regulatory developments, including broader cannabis rescheduling.

Recent Developments

• Opened five new dispensaries across core markets, including partner owned and operated locations, bringing the total retail footprint to 61 stores and exceeding the year-end target of 60 ahead of schedule. New openings include:
  • Ascend of Evesham in Marlton, New Jersey, which the Company owns and operates with a social equity partner. Two additional partner stores in the Company's New Jersey pipeline are expected to open in early 2027, subject to regulatory timing.
  • Ascend Lewis Center, Ohio, the Company's seventh store in the state.
  • A partner-owned and operated dispensary opened in Plano, Illinois in November, bringing the Company's retail footprint in the state to 17 locations, including partners.
  • Two dispensaries in Worcester and Shrewsbury, Massachusetts, which the Company began operating in October under a consulting agreement pending regulatory approval to close the acquisition. Upon closing, Ascend will gain a vertically integrated medical license, which it expects to extend to all of its Massachusetts stores and its Athol cultivation facility, allowing each of its stores in the state to serve medical patients.
• Expanded retail footprint from 39 to 61 stores² since August 2024, a net increase of approximately 60% in just over two years, driven by the Company's retail densification strategy.
• Debuted Effin' Tabs, a line of precision-dosed THC tablets and a new format for the brand, in New Jersey, Massachusetts, and Illinois.
• Closed $11 million in non-dilutive mortgage loans with CF Bank, secured by five Company-owned properties in Illinois, Maryland, and Massachusetts. The loans carry an 8.5% annual interest rate and mature in October 2031, and the Company intends to use the proceeds to support retail expansion and pursue accretive acquisition opportunities.
• Entered into a capital-light brand licensing agreement with Atlantic Cultivation, a Canadian craft cannabis producer. Through this arrangement, select products from two of the Company's flagship brands, High Wired infused pre-rolls and Ozone Liquid Diamonds vapes, are expected to reach Canadian shelves in the first quarter of 2027.

Management Commentary

"Our growth strategy continues to drive results across the business, and that momentum carried through a strong third quarter as we delivered on the goals we set," said Sam Brill, CEO & Director of AWH. "Net revenue returned to year-over-year growth despite continued pricing headwinds, and retail sales grew as a share of total revenue. Since quarter end, we also exceeded our year-end target of 60 stores ahead of schedule. That is a milestone, not a finish line, and we see ample room to keep growing our retail footprint through our densification strategy. On the brand side, Ascend remains the number two brand house across Illinois, New Jersey, and Massachusetts, combined, and we recently signed a licensing agreement to bring our brands to Canada, our first market outside of the U.S. and one of the most sophisticated and competitive cannabis markets in the world."

Frank Perullo, Founder, President & Director of AWH, added, "Sustained investment in our operations has meaningfully improved product quality across our portfolio, and it is showing up in our market share and in our revenue per gram. Each new retail door extends our consumer reach, strengthens our brands and market share positioning, and adds additional operating leverage by driving more vertical sales. All of that supports consistent cash flow generation, which remains a core goal for us in both the near term and the long term."

"Scale and profitability are moving together, and our focus on cash discipline is showing up in the results," said Roman Nemchenko, Chief Financial Officer. "We generated $5.4 million of cash flow from operations in the third quarter while also funding our $19.1 million semi-annual interest payment, a $7.4 million improvement from the third quarter of last year. Lean working capital, continuous cost management, and driving more sales through our retail channel were the largest contributors, and we expect retail growth to be a meaningful source of Adjusted EBITDA¹ and cash flow growth into 2027."

Q3 2026 Financial Overview

Net revenue totaled $130.0 million for Q3 2026, an increase of 3.1% sequentially from $126.1 million in Q2 2026 and an increase of 4.2% from $124.7 million in Q3 2025.

Retail revenue, including new store and partner contributions, was $97.8 million, a 5.5% sequential increase, driven by new store openings, while the Company's same-store portfolio followed typical third-quarter seasonality.

Third-party wholesale revenue was $32.2 million, a decrease of 3.6% sequentially, driven primarily by the work stoppage at the Company's Barry, Illinois facility, which affected deliveries for the month of July, along with lower pricing, partially offset by higher volume.

Q3 2026 gross profit was $53.1 million, or 40.8% of revenue, as compared to $45.5 million, or 36.1% of revenue, in Q2 2026. Adjusted Gross Profit¹ was $62.9 million, or 48.4% of revenue, for Q3 2026, up 220-basis points sequentially, driven by a higher mix of retail sales and benefits from operating leverage that were partially offset by continued price compression.

Net loss for Q3 2026 was $28.0 million. Comparatively, net loss was $9.8 million in Q2 2026 and reflected a one-time benefit related to a $14.8 million release from the Company's reserve for uncertain tax positions. 

Adjusted EBITDA¹ was $31.1 million in Q3 2026, compared to $29.1 million in Q2 2026, with an Adjusted EBITDA Margin¹ of 23.9%, an increase of 80-basis points sequentially. The increase was consistent with growth in net revenue and Adjusted Gross Profit¹.

Balance Sheet and Cash Flow

As of September 30, 2026, cash and cash equivalents were $63.6 million and Net Debt⁴ was $260.4 million. Net cash provided by operating activities was $5.4 million in Q3 2026, inclusive of the Company's $19.1 million semi-annual interest payment made in July, and Free Cash Flow⁵ was $2.7 million. Capital expenditures totaled $4.8 million in Q3 2026 and $15.7 million year-to-date, and full-year 2026 capital expenditures are expected to be approximately $20 million.

Outlook

For the fourth quarter of 2026, the Company anticipates a 1 to 2% increase in revenue and Adjusted EBITDA Margin¹ is expected to be consistent with Q3 2026.

(1)	Measure is a non-GAAP financial measure. Please see "Non-GAAP Financial Information and Definitions" below and "Reconciliations of Non-GAAP Financial Measures (Unaudited)" at the end of this press release.
(2)	Includes both Company owned and partner owned and operated locations, as of November 12, 2026.
(3)	Source: BDSA, reflecting AWH's share across Illinois, New Jersey, and Massachusetts combined in Q3 2026.
(4)	Net Debt is a non-GAAP financial measure defined as total debt, net of unamortized deferred financing costs of ~$324.0 million, less cash and cash equivalents of $63.6 million as of September 30, 2026. Please see "Non-GAAP Financial Information and Definitions" below.
(5)	Free Cash Flow is a non-GAAP financial measure defined as cash flows from operating activities of $5.4 million less capital expenditures of $2.7 million, which represents total additions to capital assets excluding $2.1 million related to new store builds. Please see "Non-GAAP Financial Information and Definitions" below.

Earnings Conference Call

The Company will hold a conference call today, Thursday, November 12, 2026, at 5:00 p.m. ET, to discuss its Q3 2026 results.

The call can be accessed by dialing 1-888-699-1199, and a live audio webcast will be available at this link. The webcast will also be archived for replay via the Investor Relations section of the AWH website at https://investors.awholdings.com. A telephone replay will be available by calling 1-888-660-6345 with replay code 05012 until midnight ET on Thursday, November 19, 2026.

About Ascend Wellness Holdings, Inc.

AWH is a vertically integrated cannabis operator with assets in Illinois, Maryland, Massachusetts, Michigan, New Jersey, Ohio, and Pennsylvania. AWH owns and operates state-of-the-art cultivation facilities, growing award-winning strains and producing a curated selection of products for retail and wholesale customers. AWH produces and distributes its in-house Ozone, Simply Herb, High Wired, Honor Roll, Royale, and Effin' branded products. For more information about AWH, visit www.awholdings.com.

Additional information relating to the Company's Q3 2026 results can be found on the Investor Relations section of AWH's website at https://investors.awholdings.com, the SEC's Electronic Data Gathering, Analysis, and Retrieval system ("EDGAR") at www.sec.gov and Canada's System for Electronic Document Analysis and Retrieval Plus ("SEDAR+") at www.sedarplus.ca.

Non-GAAP Financial Information and Definitions

This press release includes certain non-GAAP financial measures as defined by the U.S. Securities and Exchange Commission ("SEC"). Reconciliations of these non-GAAP financial measures to the most directly comparable financial measure calculated and presented in accordance with GAAP are included in the financial schedules attached to this press release or in other information contained herein. This information should be considered as supplemental in nature and not as a substitute for, or superior to, any measure of performance prepared in accordance with GAAP.

Adjusted EBITDA/Margin and Adjusted Gross Profit/Margin are non-GAAP financial measures. Please see "Reconciliations of Non-GAAP Financial Measures (Unaudited)" at the end of this release.

We define Net Debt as total debt, net of unamortized deferred financing costs, less cash and cash equivalents, which components are disclosed in the Company's Selected Condensed Consolidated Balance Sheet Information (Unaudited) included in the financial schedules attached to this press release under the captions "Current portion of debt, net," "Long-term debt, net," and "Cash and cash equivalents." We believe this measure is an important indicator of the Company's ability to service its long-term debt obligations. This non-GAAP financial measure should not be considered in isolation of, or as a substitute for, the most directly comparable GAAP financial measures as an indicator of operating performance or liquidity and may not be comparable to similarly titled measures provided by other companies.

We define Free Cash Flow as "Net cash provided by operating activities" net of "Additions to capital assets" which are disclosed in the Company's Selected Condensed Consolidated Cash Flow Information (unaudited) included in the financial schedules attached to this press release, adjusted for spending related to new store builds. We use Free Cash Flow measures, among other measures, to evaluate the Company's liquidity and its ability to generate cash flow. We believe that this is a meaningful financial measure to investors because it provides a view of the Company's liquidity after deducting capital expenditures, which are considered to be a necessary component of ongoing operations. This non-GAAP financial measure should not be considered in isolation of, or as a substitute for, net cash provided by operating activities and may not be comparable to similarly titled measures provided by other companies.

Cautionary Note Regarding Forward-Looking Information

This news release contains forward-looking information and forward-looking statements (collectively, "forward-looking statements") within the meaning of applicable U.S. and Canadian securities laws, which may include, but are not limited to, the plans, intentions, expectations, estimates, and beliefs of the Company. Words such as "expects", "continue(s)", "may", "will", "anticipates", "believes", "estimates", "plans", "projects", "outlook", "guidance", and "intends" or similar expressions are intended to identify forward-looking statements. Without limiting the generality of the preceding statement, all statements in this press release relating to estimated and projected revenue, expectations regarding production capacity, anticipated capital expenditures, expansion, profit, product demand, margins, costs, cash flows, sources of capital, growth rates, potential acquisitions, closing dates for transactions, regulatory approvals, future facility openings, and future financial and operating results are forward-looking statements.

Forward-looking statements in this press release also include, without limitation, statements regarding the Company's outlook for the fourth quarter of 2026 and anticipated full-year 2026 capital expenditures, the anticipated timing and outcome of the DEA's adult-use cannabis rescheduling proceeding and related federal hemp redefinition, the Company's DEA registration applications, the timing and implementation of the reverse stock split and planned uplisting to a major U.S. exchange, the anticipated closing of the Company's pending acquisition in Massachusetts and related regulatory approvals, anticipated store openings in the Company's New Jersey pipeline, the anticipated timing and markets of the Company's Canadian brand licensing arrangement, and the potential impact of the foregoing on the Company's operations and tax positions (including under Section 280E of the Internal Revenue Code).

We caution investors that any such forward-looking statements are based on the Company's current projections and expectations about future events and financial trends, the receipt of all required regulatory and stockholder approvals, and on certain assumptions, estimates, and analysis made by the Company in light of the experience of the Company and its perception of historical trends, current conditions, and expected future developments and other factors that management believes are appropriate, including, with respect to statements regarding rescheduling and uplisting, assumptions about the timing and final form of any such developments.

Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein. Such factors include, without limitation, the risks and uncertainties identified in the Company's most recently filed Annual Report on Form 10-K, as updated in subsequently filed Quarterly Reports on Form 10-Q, as applicable, and in the Company's other reports and filings with the applicable Canadian securities administrators on its profile on SEDAR+ at www.sedarplus.ca and the SEC on its profile on EDGAR at www.sec.gov. Readers are cautioned that the foregoing list of factors is not exhaustive. Although the Company believes that any forward-looking statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such statements, there can be no assurance that any such forward-looking statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking statements. Any forward-looking statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws. No securities regulator nor the Canadian Securities Exchange has reviewed, approved, or disapproved the content of this press release.

ASCEND WELLNESS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS INFORMATION (UNAUDITED)

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands, except per share amounts)	2026		2025		2026		2025
Revenue, net	$       130,019		$       124,734		$       373,070		$       380,035
Cost of goods sold	(76,930)		(81,133)		(229,608)		(255,481)
Gross profit	53,089		43,601		143,462		124,554
Operating expenses
General and administrative expenses	48,589		44,926		131,136		124,395
Operating profit (loss)	4,500		(1,325)		12,326		159
Other (expense) income
Interest expense	(21,977)		(12,562)		(63,031)		(35,810)
Other income, net	59		341		174		1,302
Total other expense, net	(21,918)		(12,221)		(62,857)		(34,508)
Loss before income taxes	(17,418)		(13,546)		(50,531)		(34,349)
Income tax expense	(10,533)		(12,279)		(16,719)		(35,141)
Net loss	$       (27,951)		$       (25,825)		$       (67,250)		$       (69,490)
Net loss per share attributable to Class A    and Class B common stockholders    — basic and diluted	$          (0.14)		$          (0.13)		$          (0.33)		$          (0.34)
Weighted-average common shares    outstanding — basic and diluted	203,234		202,970		202,897		203,943

ASCEND WELLNESS HOLDINGS, INC.
CONDENSED CONSOLIDATED CASH FLOWS INFORMATION (UNAUDITED)

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2026		2025		2026		2025
Net cash provided by (used in) operating    activities	$         5,429		$        (2,003)		$         8,469		$        21,737
Cash flows from investing activities
Additions to capital assets	(4,791)		(6,449)		(15,749)		(19,115)
Investments in notes receivable	—		(285)		—		(285)
Proceeds from collection of notes receivable	—		4,181		3,027		4,345
Proceeds from sale of assets	—		—		1,000		27
Payments for acquisition of businesses and    related deposits, net of cash acquired	(2,470)		(5,984)		(11,230)		(9,445)
Purchase of intangible assets	(1,300)		(4,000)		(3,450)		(4,500)
Net cash used in investing activities	(8,561)		(12,537)		(26,402)		(28,973)
Cash flows from financing activities
Proceeds from issuance of debt	—		9,345		—		72,412
Repayments of debt	(45)		(1,627)		(137)		(61,962)
Debt issuance costs	—		(102)		—		(462)
Repayments under finance leases	(211)		(548)		(730)		(1,395)
Taxes withheld under equity-based    compensation plans, net	—		—		(346)		—
Repurchase of common stock	—		(586)		—		(1,580)
Proceeds from the exercise of stock options	13		60		40		60
Payment of contingent consideration	—		—		(2,945)		(819)
Net cash (used in) provided by financing    activities	(243)		6,542		(4,118)		6,254
Net decrease in cash, cash equivalents, and    restricted cash	(3,375)		(7,998)		(22,051)		(982)
Cash, cash equivalents, and restricted    cash at beginning of period	67,000		95,270		85,676		88,254
Cash, cash equivalents, and restricted    cash at end of period	$        63,625		$        87,272		$        63,625		$        87,272

ASCEND WELLNESS HOLDINGS, INC.
SELECTED CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION (UNAUDITED)

(in thousands)	September 30, 2026		December 31, 2025
Cash and cash equivalents	$              63,625		$               85,676
Inventory	82,794		84,707
Other current assets	34,772		38,566
Property and equipment, net	376,015		382,402
Operating lease right-of-use assets	47,851		47,063
Intangible assets, net	191,456		196,072
Goodwill	71,129		58,453
Other non-current assets	12,157		14,990
Total Assets	$             879,799		$             907,929
Current portion of debt, net	$              29,336		$              10,368
Other current liabilities	86,978		98,641
Long-term debt, net	294,723		291,104
Operating lease liabilities, non-current	61,065		60,546
Finance lease liabilities and other lease financing liabilities, non-    current	269,778		261,913
Other non-current liabilities	250,327		231,974
Total stockholders' deficit	(112,408)		(46,617)
Total Liabilities and Stockholders' Deficit	$             879,799		$             907,929

ASCEND WELLNESS HOLDINGS, INC.
RECONCILIATIONS OF NON-GAAP FINANCIAL MEASURES (UNAUDITED)

          We define "Adjusted Gross Profit" as gross profit excluding non-cash inventory costs, which include depreciation and amortization included in cost of goods sold, equity-based compensation included in cost of goods sold, and other non-cash inventory adjustments. We define "Adjusted Gross Profit Margin" as Adjusted Gross Profit as a percentage of net revenue. Our "Adjusted EBITDA" is a non-GAAP measure used by management that is not defined by GAAP and may not be comparable to similar measures presented by other companies. We define "Adjusted EBITDA Margin" as Adjusted EBITDA as a percentage of net revenue. Management calculates Adjusted EBITDA as the reported net loss, adjusted to exclude: income tax expense, other (income) expense, interest expense, depreciation and amortization, depreciation and amortization included in cost of goods sold, non-cash inventory adjustments, equity-based compensation, equity-based compensation included in cost of goods sold, start-up costs, start-up costs included in cost of goods sold, transaction-related and other non-recurring expenses, gain or loss on sale of assets, and litigation settlement, as applicable. Accordingly, management believes that Adjusted EBITDA provides meaningful and useful financial information, as this measure demonstrates the operating performance of the business. The tables below provide reconciliations of these non-GAAP measures to the most comparable U.S. GAAP financial measure. Non-GAAP financial measures may be considered in addition to the results prepared in accordance with U.S. GAAP, but they should not be considered a substitute for, or superior to, U.S. GAAP results. The Company's presentation of these financial measures may not be comparable to similar non-GAAP measures used by other companies. These financial measures are intended to provide additional information to investors regarding the Company's performance.

          The following table presents Adjusted Gross Profit for the three and nine months ended September 30, 2026 and 2025:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in thousands)	2026		2025		2026		2025
Gross Profit	$     53,089		$     43,601		$    143,462		$    124,554
Depreciation and amortization     included in cost of goods sold	9,237		6,928		27,837		25,209
Equity-based compensation included    in cost of goods sold	335		329		1,370		1,631
Non-cash inventory adjustments(1)	219		6,967		2,429		13,883
Adjusted Gross Profit	$     62,880		$     57,825		$    175,098		$    165,277
Adjusted Gross Profit Margin	48.4 %		46.4 %		46.9 %		43.5 %

(1)	Consists of write-offs of expired products, obsolete packaging, and net realizable value adjustments related to certain inventory items.

ASCEND WELLNESS HOLDINGS, INC.
RECONCILIATIONS OF NON-GAAP FINANCIAL MEASURES (UNAUDITED)

          The following table presents Adjusted EBITDA for the three and nine months ended September 30, 2026 and 2025:

	Three Months Ended  September 30,				Nine Months Ended September 30,
($ in thousands)	2026		2025		2026		2025
Net loss	$    (27,951)		$    (25,825)		$    (67,250)		$    (69,490)
Income tax expense	10,533		12,279		16,719		35,141
Other income, net	(59)		(341)		(174)		(1,302)
Interest expense	21,977		12,562		63,031		35,810
Depreciation and amortization	20,206		16,771		59,540		53,001
Non-cash inventory adjustments(1)	219		6,967		2,429		13,883
Equity-based compensation	659		806		1,985		2,610
Start-up costs(2)	3,543		4,092		9,987		8,708
Transaction-related and other non-    recurring expenses(3)	2,012		3,783		438		8,251
(Gain) loss on sale of assets	—		—		(137)		55
Adjusted EBITDA	$     31,139		$     31,094		$     86,568		$     86,667
Adjusted EBITDA Margin	23.9 %		24.9 %		23.2 %		22.8 %

(1)	Consists of write-offs of expired products, obsolete packaging, and net realizable value adjustments related to certain inventory items.
(2)	One-time costs associated with acquiring real estate, obtaining licenses and permits, and other costs incurred before commencement of operations at certain locations, as well as incremental expenses associated with the expansion of activities at our cultivation facilities that are not yet operating at scale, other expenses resulting from delays in regulatory approvals, and other related one-time or non-recurring expenses, as applicable. The three and nine months ended September 30, 2026 includes $2,477 and $7,317, respectively, of unallocated overhead expenses at certain cultivation facilities resulting from a rebalancing of overhead expenses from cost of goods sold to general and administrative expenses based on overhead allocations relative to production output at those locations, compared with $3,580 and $6,693 during the three and nine months ended September 30, 2025, respectively.
(3)	Other non-recurring expenses including legal and professional fees associated with litigation matters, potential acquisitions, other regulatory matters, and other reserves or one-time expenses, including certain non-recurring professional fees associated with certain strategic initiatives. The three and nine months ended September 30, 2026 include $725 of severance. The three and nine months ended September 30, 2026 include $37 and $314, respectively, related to property development expense write-offs, and the nine months ended September 30, 2026 includes a net reduction related to acquisition-related earn-out fair value adjustments of approximately $4,953. The nine months ended September 30, 2025 include approximately $700 of expenses associated with our May 2025 term loans and approximately $400 of expenses associated with our January 2025 term loans. The three and nine months ended September 30, 2025 also include approximately $170 and $270, respectively, of fair value adjustments associated with acquisition earn-outs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/awh-reports-third-quarter-2026-financial-results-302938358.html

SOURCE Ascend Wellness Holdings, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Ascend Wellness Holdings' Q3 2026 revenue and net loss?

Ascend reported $130.0 million in revenue and a $28.0 million net loss for the quarter ended September 30, 2026. Revenue increased 4.2% year-over-year and 3.1% sequentially. The preceding quarter's $9.8 million net loss included a $14.8 million benefit from releasing a reserve for uncertain tax positions.

What is AAWH's outlook for Q4 2026?

Ascend anticipates a 1 to 2% increase in revenue for Q4 2026 and expects its adjusted EBITDA margin to remain consistent with Q3 2026. The Q3 adjusted EBITDA margin was 23.9%.

How does Ascend calculate its Q3 2026 free cash flow?

Ascend's $2.7 million non-GAAP free cash flow subtracts $2.7 million of capital expenditures from $5.4 million of operating cash flow. That capital-spending measure excludes $2.1 million related to new store builds; total Q3 capital expenditures were $4.8 million.

Has AAWH set a reverse stock split ratio or effective date?

The approved reverse split has no specified ratio or effective date; the board has flexibility to set both. Stockholders approved the Class A common share reverse split on August 28, 2026. Ascend intends to use it to support a potential major U.S. exchange listing, subject to regulatory developments, including broader cannabis rescheduling.